US 12,295,973 B2
Luteinizing hormone receptor binding agents and luteinizing hormone agonists to identify, expand, ablate and modify stem cells
Jarrod Dudakov, Seattle, WA (US); Marcel van den Brink, New York, NY (US); Enrico Velardi, New York, NY (US); Hans-Peter Kiem, Seattle, WA (US); Stefan Radtke, Seattle, WA (US); and Scott James, New York, NY (US)
Assigned to Fred Hutchinson Cancer Center, Seattle, WA (US); and Memorial Sloan-Kettering Cancer Center, New York, NY (US)
Filed by Fred Hutchinson Cancer Center, Seattle, WA (US); and Memorial Sloan-Kettering Cancer Center, New York, NE (US)
Filed on Jun. 12, 2023, as Appl. No. 18/208,490.
Application 18/208,490 is a continuation of application No. 16/753,277, granted, now 11,786,557, previously published as PCT/US2018/054004, filed on Oct. 2, 2018.
Claims priority of provisional application 62/566,897, filed on Oct. 2, 2017.
Prior Publication US 2024/0091265 A1, Mar. 21, 2024
Int. Cl. A61K 35/28 (2015.01); A61K 35/12 (2015.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C12N 5/0789 (2010.01); C12N 15/86 (2006.01)
CPC A61K 35/28 (2013.01) [A61K 35/12 (2013.01); A61K 39/461 (2023.05); A61K 39/4621 (2023.05); A61K 39/46431 (2023.05); A61P 35/00 (2018.01); C12N 5/0647 (2013.01); C12N 15/86 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05)] 18 Claims
 
1. A cDNA comprising a sequence as set forth in SEQ ID NO: 19 or SEQ ID NO: 6 or a sequence having at least 90% sequence identity to SEQ ID NO: 19 or SEQ ID NO: 6.